Association between Peripheral Lymphocyte Count and the Mortality Risk of COVID-19

2020 ◽  
Author(s):  
Saibin Wang ◽  
Yijun Sheng ◽  
Junwei Tu ◽  
Lanlan Zhang
Keyword(s):  
Mortality Risk ◽  
Lymphocyte Count ◽  
Peripheral Lymphocyte

scholarly journals Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Ye Jin Lee ◽  
Young Sik Park ◽  
Hyun Woo Lee ◽  
Tae Yoen Park ◽  
Jung Kyu Lee ◽  
...  
Keyword(s):  
Adverse Events ◽  
Lymphocyte Count ◽  
Unmet Need ◽  
Surrogate Marker ◽  
Progression Free Survival ◽  
Peripheral Lymphocyte ◽  
Post Treatment ◽  
Before And After ◽  
Check Point Inhibitors ◽  
Nsclc Patients

AbstractDegree of expression of programmed death-ligand 1 (PD-L1) is related with Immune check point inhibitors (ICIs) response but it needs sufficient tumor tissue. There is unmet need for easily accessible and prognostic peripheral blood (PB) biomarkers. We investigated the application of serum peripheral lymphocyte count (PLC) as a predictive PB biomarker for ICI response in patients with NSCLC. We conducted a retrospective study and reviewed the patients with NSCLC who were treated with ICIs from April 1, 2016, to March 31, 2019. The PLC before and after 1 month of immunotherapy was collected. We evaluated the association between PLC and progression-free survival (PFS), overall survival (OS) and adverse events. A total of 231 patients were treated with ICIs for NSCLC. The median follow-up period was 4.7 months and the disease progressed in 138 patients (59.7%). Compared with the lowest quartile (Q1: the lowest 25%), the highest quartile (Q4: the highest 25%) of post-treatment PLC showed a significantly higher PFS (HR 0.28, 95% CI 0.16–0.52) and OS (HR 0.35, 95% CI 0.19–0.65) in the adjusted model. An association between adverse events and PLC was not observed. We revealed that an increased pre- and post-treatment PLC was associated with favorable PFS and OS with NSCLC patients treated with ICIs. PLC could be a helpful for ICI responses in NSCLC.

Total Peripheral Lymphocyte Count in Malignant Tumors: An Index of Prognostication

2011 ◽  
Vol 12 (1) ◽  
pp. 24-28 ◽  
Author(s):  
S. Shamshad Ahmad ◽  
Kafil Akhtar ◽  
A.K. Verma ◽  
Amjad Zia Mallik ◽  
Shahid Ali Siddiqui
Keyword(s):  
Lymphocyte Count ◽  
Malignant Tumors ◽  
Peripheral Lymphocyte

Lymphocyte Count and Mortality Risk in Older Persons. The Leiden 85-Plus Study

2003 ◽  
Vol 51 (10) ◽  
pp. 1461-1465 ◽  
Author(s):  
Gerbrand J. Izaks ◽  
Edmond J. Remarque ◽  
Sander V. Becker ◽  
Rudi G. J. Westendorp
Keyword(s):  
Mortality Risk ◽  
Lymphocyte Count ◽  
Older Persons

scholarly journals Impact of Peripheral Lymphocyte Count on the Sensitivity of 2 IFN-γ Release Assays, QFT-G and ELISPOT, in Patients with Pulmonary Tuberculosis

2010 ◽  
Vol 49 (17) ◽  
pp. 1849-1855 ◽  
Author(s):  
Kosaku Komiya ◽  
Haruyuki Ariga ◽  
Hideaki Nagai ◽  
Shinji Teramoto ◽  
Atsuyuki Kurashima ◽  
...  
Keyword(s):  
Pulmonary Tuberculosis ◽  
Lymphocyte Count ◽  
Peripheral Lymphocyte ◽  
Ifn Γ

scholarly journals The Peripheral Lymphocyte Count as an Aid in the Clinical Staging of Lung Cancer

1978 ◽  
Vol 187 (3) ◽  
pp. 248-250 ◽  
Author(s):  
SCOTT P. AARONS ◽  
WILLIAM A. ALBANO ◽  
RANDALL E. HARRIS ◽  
CLAUDE H. ORGAN
Keyword(s):  
Lung Cancer ◽  
Lymphocyte Count ◽  
Peripheral Lymphocyte ◽  
Clinical Staging
Sign in / Sign up

Export Citation Format

Share Document